Helixgate

Helixgate

Uncategorized

Bristol Myers reaches a crossroads as a make-or-break year takes shape

Published

on

Bristol Myers Squibb is facing a bit of an identity crisis.

CEO Chris Boerner is nearly two and a half years into his tenure, with most of his time defined by

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee

Published

on

Members of the FDA’s Oncologic Drugs Advisory Committee questioned the design of AstraZeneca’s Phase 3 trial of camizestrant, which involved switching treatments at the point of mutation detection, as opposed to the current practice of changing regimens upon disease progression.

Continue Reading

Uncategorized

Corcept ties ALS drug to improved 2-year survival as Phase 3 start date nears

Published

on

Corcept Therapeutics’ ALS drug was linked to an 87% reduction in the risk of death, a result the biotech hopes to replicate in an upcoming Phase 3 trial.

Continue Reading

Uncategorized

Seaport, Hemab price IPOs, while Avalyn soars in Nasdaq debut

Published

on

A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million combined.

Seaport Therapeutics, Hemab Therapeutics and Avalyn Pharma are the …

Continue Reading
Advertisement

Trending